Sahajanand Medical Technologies
- P/E
- 71.2x
- 52-week range
- 346.65 – 565.75
- ROE
- 10%
- ROCE
- 11%
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 26 companies →Sahajanand Medical Technologies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)71.2 against a typical 30.3: pricier than most peers (1st = cheapest).24th of 26
Latest announcements
Exchange filings and their impact on the company.
- SMT received a GST inquiry summons with no demand raised and no material impact disclosed.
AIAI analysisNeutral for shareholdersLow impact SMT received a GST inquiry summons with no demand raised and no material impact disclosed.
Sahajanand Medical Technologies said it received a summons dated October 16, 2026 from the DGGI Mumbai Zonal Unit under Section 70 of the CGST Act in connection with an inquiry. The summons was received on October 23, 2026. The company said it is fully cooperating with authorities, sees no material financial impact at this stage, and will update on any significant developments.
Why it matters: The summons is an initial inquiry under Section 70 of the CGST Act with no amount demanded, so no measurable 12-month financial effect can be estimated and the company states no material financial impact.
For shareholders: No tax demand, penalty or liability has been quantified and the company states no material financial impact at this inquiry stage.
Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions.
Sahajanand Medical Technologies said it received a summons dated October 16, 2026 from the DGGI Mumbai Zonal Unit under Section 70 of the CGST Act in connection with an inquiry. The summons was received on October 23, 2026. The company said it is fully cooperating with authorities, sees no material financial impact at this stage, and will update on any significant developments.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Adequate safety
Rated A- by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil A- | Stable | 3 Nov 2026 |
| Rating | Details | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Nov 2026 | ▲ Upgrade | Crisil A- | Low | CRISIL | ₹ 300 Cr. | |||||||||||||
Rating details
CRISIL upgraded SMT to A-/Stable on stronger scale and profitability and raised rated bank limits to Rs 300 crore. CRISIL upgraded Sahajanand Medical Technologies' bank facilities to Crisil A-/Stable for long term and Crisil A2+ for short term, from BBB+/A2, and increased the rated amount to Rs 300 crore from Rs 280 crore. The agency cited 18% revenue growth to Rs 1,214 crore in FY26, stable operating margin around 13.1%, and healthy gearing of 0.43 times. The upgrade should modestly reduce borrowing costs and support liquidity, with no major near-term change to sales or operations. Why it matters: One-notch upgrade from BBB+ to A- on Rs 300 cr facilities reflects FY26 revenue of Rs 1214 cr and 13.1% margin but itself only trims interest cost by ~Rs 0.5-1 cr and does not directly add revenue. For shareholders: Upgrade validates 18% revenue growth and stable margins and should modestly lower borrowing costs and improve funding access. Estimated effect over the next 12 months
Generated by AI from the original document. It can be wrong or incomplete and is not investment advice. Check the source before acting on it. Estimates are rough projections, not forecasts by Minerva Capital Research Solutions. | ||||||||||||||||||
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 5 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Jun 2026 |
|---|---|
| Sales | 352 |
| Expenses | 303 |
| Operating Profit | 49 |
| OPM % | 14% |
| Other Income | 3 |
| Interest | 7 |
| Depreciation | 20 |
| Profit before tax | 24 |
| Tax % | 38% |
| Net Profit | 15 |
| EPS in Rs | 1.44 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 16%
- 3 Years
- —
- TTM
- 18%
- 10 Years
- —
- 5 Years
- 27%
- 3 Years
- —
- TTM
- 180%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 4%
- TTM
- —
P/E and EPS over time
Daily price to earnings ratio.
Prices are delayed and for information only. Nothing on this page is investment advice.